Clinical Trial Results: A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Pexa-Vec (JX-594) given before Sorafenib for unresectable primary hepatocellular carcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pexa-Vec (pexastimogene devacirep)

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED | Results posted: 2026-07-14